Orexo and Uppsala University receive Swedish Research Council grant for bioceramics project

Uppsala, November 30 2011 - Orexo AB (STO: ORX) has been awarded a 2.1 million SEK grant from the Swedish Research Council for the project "Bioceramic materials for slow release of potent drugs". The project will be conducted between 2012 and 2015 in collaboration with a research team, led by Professor Håkan Engqvist, Applied Materials Science, Department of Engineering Sciences at Uppsala University.

The aim of the project is to study ceramic materials in order to develop new oral products for pain management. The project will increase knowledge and understanding of the technology platform based on ceramic materials. Orexo and the research group are focused on developing a technology platform for safe dosing of opioids. Uppsala University contributes to the project with knowledge of material properties, while Orexo contributes with pharmaceutical expertise in controlled drug release and product development.

"It's great that we, together with Orexo, have received the Swedish Research Council's support for the development of new knowledge that can be used to develop new and safer administration of drugs," says Professor Håkan Engqvist.

"This grant gives us new resources for our collaboration with researchers at the Department of Engineering Sciences and we hope to be able to more rapidly develop a new technology platform for dosing of highly potent drugs," says Thomas Lundqvist, Head of Pharmaceutical Research & Development at Orexo.

For further information, please contact:
Anders Lundström, President and CEO, Orexo AB
Tel: +46 706 67 22 66
E-mail: [email protected]

Thomas Lundqvist, EVP and Head of Pharmaceutical Research & Development, Orexo AB
Tel: +46 705 31 83 41
E-mail: [email protected]

About the Swedish Research Council and the statistics for successful applications: www.vr.se.

About Orexo
Orexo is a pharmaceutical company focusing on developing treatments for pain and inflammation. The company has four commercialized products, several projects developed in partnership as well as three proprietary development programs. Orexo’s registered products are Abstral® for the treatment of break through cancer pain, sold by Kyowa Hakko Kirin/ProStrakan Group plc. in Europe and in the USA, the sleeping pill Edluar™, sold by Meda in the USA, as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary Kibion. More information can be found at www.orexo.com.

Note
Orexo AB (publ) discloses the information provided in this press release pursuant to the Securities Markets Act. The information was provided for public release on November 30, 2011 at 08:00a.m. CET. This press release has been prepared in both Swedish and English. In the event of any discrepancy in the content of the two versions, the Swedish version shall take precedence.